Table 4.
Variable | OS |
PFS |
||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | |
Age (≥65 yr) | 1.00 | 0.37–2.76 | 0.993 | 1.02 | 0.38–2.75 | 0.965 |
Sex (female) | 0.77 | 0.31–1.91 | 0.567 | 0.78 | 0.31–1.96 | 0.603 |
ECOG PS (≥2) | 1.13 | 0.43–3.00 | 0.807 | 1.07 | 0.40–2.86 | 0.899 |
Stage (IVA vs. others) | 0.03 | 0.00–11.7 | 0.253 | 0.03 | 0.00–11.8 | 0.253 |
IMRT | 0.58 | 0.22–1.49 | 0.254 | 0.68 | 0.27–1.72 | 0.413 |
Chemotherapy | 0.07 | 0.01–0.35 | 0.001* | 0.14 | 0.04–0.49 | 0.002* |
EQD210 dose (≥62 Gy) | 0.16 | 0.05–0.53 | 0.003* | 0.32 | 0.11–0.90 | 0.031* |
RT, radiation therapy; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; IMRT, intensity-modulated radiotherapy; OS, overall survival; PFS, progression-free survival.
p < 0.05.